Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized comparison of gemcitabine + carboplatin versus cisplatin + etoposide in small cell lung cancer
ISRCTN39679215Phase 3Completed
- Sponsor
- National Clinical Research Institute
- Start
- Jan 1996
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of gemcitabine, carboplatin, cisplatin and etoposide in small cell lung cancer (SCLC), sponsored by National Clinical Research Institute. Started Jan 1996; status: completed.
02
Drugs
gemcitabinecarboplatincisplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ISRCTN39679215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN39679215.